A Phase 2 interventional study of Cisplatin and Panitumumab in Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck, sponsored by Amgen. Completed at 114 sites in 9 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-10-17.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing panitumumab in Neoplasm Metastasis — 1 open to participants now, 2 under way, none of them phase 3. Panitumumab · Neoplasm Metastasis.
Among the 20 studies testing panitumumab in Neoplasm Metastasis, this one is the 11th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2007, is one of 17 in phase 2, and was the 11th registered.
4,048 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.
Browse Neoplasm Metastasis studies →1 of the 20 studies testing panitumumab in Neoplasm Metastasis is open now, in 2 countries. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
By country, each count listing its studies:
Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 691 Neoplasm Metastasis studies recruiting now, 538 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 113 is above the median of 50 across 3,273 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 116 across the 19 interventional studies. Of the 18 that completed or were terminated, 12 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 20 have an industry lead sponsor. The 6 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
31 studies in Neoplasm Metastasis by Amgen: 1 open now, 1 under way, none of them phase 3. Of 30 finished, 16 (53%) have results posted.
Among the 31 studies in Neoplasm Metastasis by Amgen, this one is the 17th largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2007, is one of 16 in phase 2, and was the 16th registered.
Amgen’s Neoplasm Metastasis studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing panitumumab in Neoplasm Metastasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 31 in Neoplasm Metastasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, open-label, 2-arm, controlled, phase 2, multi-center, estimation clinical trial of docetaxel and cisplatin combination chemotherapy with and without panitumumab in the first-line treatment of subjects with metastatic or recurrent head and neck cancer, as well as a cross-over second-line panitumumab monotherapy of subjects who fail the chemotherapy only arm. This study will be conducted in the United States. Approximately 150 subjects with histologically or cytologically confirmed metastatic and/or recurrent SCCHN.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any co-morbid disease that would increase risk of toxicity
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Panitumumab + Docetaxel + Cisplatin
Drug: Panitumumab · Drug: Cisplatin · Drug: Docetaxel
control
Drug: Cisplatin · Drug: Docetaxel
chemotherapy arm
experimental arm
chemotherapy arm
experimental arm
experimental arm
Progression Free Survival (PFS) During the First-line Treatment Phase
The time from the date of randomization to the date of first disease progression determined by the investigators per modified RECIST v1.0, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever is later) during the first-line treatment phase.
Time frame: Every 6 weeks until disease progression or death, up to 67 months
Overall Response Rate (ORR) During the First-line Treatment Phase
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter (SLD) of target lesions from baseline; Overall Response (OR) = CR + PR. An overall response of CR or PR must be confirmed at least 4 weeks after the criteria for response are first met. ORR is the percentage of subjects with an overall response among the analysis population.
Time frame: Every 6 weeks until disease progression or death, up to 67 months
Rate of Disease Control (RDC) During the First-line Treatment Phase
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter (SLD) of target lesions from baseline; Disease Progression (PD), \>=20% increase in the SLD of target lesions from nadir; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. An overall response of CR or PR must be confirmed at least 4 weeks after the criteria for response are first met. A best overall response of SD requires a visit response of SD or better no earlier than 35 days after randomization. RCD is the percentage of subjects with a best overall response of CR, PR or SD among the analysis population.
Time frame: Every 6 weeks until disease progression or death, up to 67 months
Duration of Response (DOR) During the First-line Treatment Phase
Calculated only for the subset of subjects who have an overall response of CR or PR while on first-line treatment phase (subsequently confirmed at least 4 weeks thereafter), and is defined as time from the first CR or PR to the first observed disease progression by a modified RECIST v1.0. Subjects not meeting the criteria for progression by the analysis data cutoff date will be censored at their last evaluable disease assessment date.
Time frame: Every 6 weeks until disease progression or death, up to 67 months
Time to Response (TTR) During the First-line Treatment Phase
Time from the date of randomization to the first CR or PR during first line treatment phase (subsequently confirmed at least 4 weeks thereafter)
Time frame: Every 6 weeks until disease progression or death, up to 67 months
Overall Survival (OS) for the First-line Treatment
Time from the date of randomization to the date of death during the entire study
Time frame: Until death, up to 67 months
Progression Free Survival (PFS) During the Second-line Treatment Phase
The time from the first dose of panitumumab monotherapy to the date of first disease progression determined by the investigators per modified RECIST v1.0, or death within 60 days after the last evaluable tumor assessment or the second-line first dose date (whichever is later) during the second-line treatment phase.
Time frame: Every 6 weeks until disease progression or death, up to 57 months
Overall Response Rate (ORR) During the Second-line Treatment Phase
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter (SLD) of target lesions from baseline; Overall Response (OR) = CR + PR. An overall response of CR or PR must be confirmed at least 4 weeks after the criteria for response are first met. ORR is the percentage of subjects with an overall response among the analysis population.
Time frame: Every 6 weeks until disease progression or death, up to 57 months
Rate of Disease Control (RDC) During the Second-line Treatment Phase
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter (SLD) of target lesions from baseline; Disease Progression (PD), \>=20% increase in the SLD of target lesions from nadir; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. An overall response of CR or PR must be confirmed at least 4 weeks after the criteria for response are first met. A best overall response of SD requires a visit response of SD or better no earlier than 35 days after the first dose date in second-line treatment. RCD is the percentage of subjects with a best overall response of CR, PR or SD among the analysis population.
Time frame: Every 6 weeks until disease progression or death, up to 57 months
Duration of Response (DOR) During the Second-line Treatment Phase
Time from the first CR or PR to the first observed disease progression by a modified RECIST v1.0. Subjects not meeting the criteria for progression by the analysis data cutoff date will be censored at their last evaluable disease assessment date.
Time frame: Every 6 weeks until disease progression or death, up to 57 months
Time to Response (TTR) During the Second-line Treatment Phase
Time from the first dose of panitumumab monotherapy to the first CR or PR during second-line treatment phase (subsequently confirmed at least 4 weeks thereafter)
Time frame: Every 6 weeks until disease progression or death, up to 57 months
Overall Survival (OS) for the Second-line Treatment
Time from the first dose of panitumumab monotherapy to the date of death during the entire study
Time frame: Until death, up to 57 months
Subjects were enrolled from 29 January 2007 to 1 September 2010.
| Milestone | Panitumumab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| Started | 56 | 57 |
| Received study medication | 56 | 55 |
| Completed | 51 | 49 |
| Not completed | 5 | 8 |
| Withdrew: Lack of efficacy | 0 | 2 |
| Withdrew: Withdrawal by subject | 2 | 4 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Ended follow-up prior to analysis | 1 | 1 |
| Withdrew: Ongoing | 1 | 0 |
| Milestone | Panitumumab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| Started | 0 | 30 |
| Completed | 0 | 27 |
| Not completed | 0 | 3 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Ended follow-up prior to analysis | 0 | 1 |
| Withdrew: Ongoing | 0 | 1 |
The time from the date of randomization to the date of first disease progression determined by the investigators per modified RECIST v1.0, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever is later) during the first-line treatment phase.
| Months | Panitumumab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| Progression Free Survival (PFS) During the First-line Treatment Phase | 6.9 (4.7 to 8.3) | 5.5 (4.1 to 6.8) |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter (SLD) of target lesions from baseline; Overall Response (OR) = CR + PR. An overall response of CR or PR must be confirmed at least 4 weeks after the criteria for response are first met. ORR is the percentage of subjects with an overall response among the analysis population.
| Percentage of Participants | Panitumumab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| Overall Response Rate (ORR) During the First-line Treatment Phase | 44.23 (30.73 to 57.73) | 37.25 (23.99 to 50.52) |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter (SLD) of target lesions from baseline; Disease Progression (PD), \>=20% increase in the SLD of target lesions from nadir; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. An overall response of CR or PR must be confirmed at least 4 weeks after the criteria for response are first met. A best overall response of SD requires a visit response of SD or better no earlier than 35 days after randomization. RCD is the percentage of subjects with a best overall response of CR, PR or SD among the analysis population.
| Percentage of Participants | Panitumumab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| Rate of Disease Control (RDC) During the First-line Treatment Phase | 80.77 (70.06 to 91.48) | 72.55 (60.30 to 84.80) |
Calculated only for the subset of subjects who have an overall response of CR or PR while on first-line treatment phase (subsequently confirmed at least 4 weeks thereafter), and is defined as time from the first CR or PR to the first observed disease progression by a modified RECIST v1.0. Subjects not meeting the criteria for progression by the analysis data cutoff date will be censored at their last evaluable disease assessment date.
| Months | Panitumumab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| Duration of Response (DOR) During the First-line Treatment Phase | 8.0 (5.7 to 11.1) | 5.1 (4.4 to 7.2) |
Time from the date of randomization to the first CR or PR during first line treatment phase (subsequently confirmed at least 4 weeks thereafter)
| Weeks | Panitumumab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| Time to Response (TTR) During the First-line Treatment Phase | 8.8 ± 3.9 | 10.6 ± 6.1 |
Time from the date of randomization to the date of death during the entire study
| Months | Panitumumab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| Overall Survival (OS) for the First-line Treatment | 12.9 (9.4 to 18.5) | 13.8 (11.8 to 22.9) |
The time from the first dose of panitumumab monotherapy to the date of first disease progression determined by the investigators per modified RECIST v1.0, or death within 60 days after the last evaluable tumor assessment or the second-line first dose date (whichever is later) during the second-line treatment phase.
| Months | Panitumumab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| Progression Free Survival (PFS) During the Second-line Treatment Phase | — | 4.2 (1.5 to 7.6) |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter (SLD) of target lesions from baseline; Overall Response (OR) = CR + PR. An overall response of CR or PR must be confirmed at least 4 weeks after the criteria for response are first met. ORR is the percentage of subjects with an overall response among the analysis population.
| Percentage of Participants | Panitumumab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| Overall Response Rate (ORR) During the Second-line Treatment Phase | — | 13.33 (1.17 to 25.50) |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter (SLD) of target lesions from baseline; Disease Progression (PD), \>=20% increase in the SLD of target lesions from nadir; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. An overall response of CR or PR must be confirmed at least 4 weeks after the criteria for response are first met. A best overall response of SD requires a visit response of SD or better no earlier than 35 days after the first dose date in second-line treatment. RCD is the percentage of subjects with a best overall response of CR, PR or SD among the analysis population.
| Percentage of Participants | Panitumumab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| Rate of Disease Control (RDC) During the Second-line Treatment Phase | — | 53.33 (35.48 to 71.19) |
Time from the first CR or PR to the first observed disease progression by a modified RECIST v1.0. Subjects not meeting the criteria for progression by the analysis data cutoff date will be censored at their last evaluable disease assessment date.
| Months | Panitumumab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| Duration of Response (DOR) During the Second-line Treatment Phase | — | NA (5.1 to NA) |
Time from the first dose of panitumumab monotherapy to the first CR or PR during second-line treatment phase (subsequently confirmed at least 4 weeks thereafter)
| Weeks | Panitumumab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| Time to Response (TTR) During the Second-line Treatment Phase | — | 10.6 ± 5.6 |
Time from the first dose of panitumumab monotherapy to the date of death during the entire study
| Months | Panitumumab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| Overall Survival (OS) for the Second-line Treatment | — | 8.5 (6.5 to 13.2) |
Collected over The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date of the first-line treatment. The median time frame is 4.5 months for Panitumumab Plus Chemotherapy arm and 4.4 months for Chemotherapy Alone arm.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Panitumumab Plus Chemotherapy | — | 34/56 (60.7%) | 54/56 (96.4%) |
| Chemotherapy Alone | — | 27/55 (49.1%) | 53/55 (96.4%) |
| Event | Panitumumab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| DehydrationMetabolism and nutrition disorders | 8/56 | 2/55 |
| PneumoniaInfections and infestations | 4/56 | 6/55 |
| DiarrhoeaGastrointestinal disorders | 6/56 | 2/55 |
| HypotensionVascular disorders | 5/56 | 0/55 |
| Febrile neutropeniaBlood and lymphatic system disorders | 3/56 | 4/55 |
| NauseaGastrointestinal disorders | 2/56 | 4/55 |
| VomitingGastrointestinal disorders | 2/56 | 4/55 |
| PyrexiaGeneral disorders | 2/56 | 4/55 |
| AnaemiaBlood and lymphatic system disorders | 1/56 | 3/55 |
| NeutropeniaBlood and lymphatic system disorders | 3/56 | 3/55 |
| Event | Panitumumab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| NauseaGastrointestinal disorders | 34/56 | 33/55 |
| FatigueGeneral disorders | 28/56 | 28/55 |
| AnaemiaBlood and lymphatic system disorders | 22/56 | 27/55 |
| DiarrhoeaGastrointestinal disorders | 25/56 | 16/55 |
| HypomagnesaemiaMetabolism and nutrition disorders | 23/56 | 13/55 |
| RashSkin and subcutaneous tissue disorders | 21/56 | 2/55 |
| Decreased appetiteMetabolism and nutrition disorders | 20/56 | 10/55 |
| VomitingGastrointestinal disorders | 15/56 | 18/55 |
| AlopeciaSkin and subcutaneous tissue disorders | 18/56 | 14/55 |
| HypokalaemiaMetabolism and nutrition disorders | 17/56 | 6/55 |
| Age, Continuous(Years) | Panitumumab Plus Chemotherapy | Chemotherapy Alone | Total |
|---|---|---|---|
| Mean | 58.2 ± 8.6 | 58.9 ± 7.4 | 58.6 ± 8.0 |
| Sex: Female, Male(Participants) | Panitumumab Plus Chemotherapy | Chemotherapy Alone | Total |
|---|---|---|---|
| Female | 9 | 5 | 14 |
| Male | 47 | 52 | 99 |
Showing the first 100 of 114 sites across 9 countries. Choose a country and city above to see the rest.
Ran from Jan 2007 to primary completion in Jun 2012, 65 months.
Results were first posted in Feb 2014, 1 year 7 months after primary completion. A results delay was requested in Aug 2011.
Of 88 industry-sponsored phase 2 interventional studies under Neoplasm Metastasis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 63. This study's 65 months is above that.
Counting every sponsor, half of 443 studies reached it within 56 months; a quarter within 33 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Panitumumab